Publication details

c-Myb increases resistance of colon carcinoma cells to cisplatin by activation of MAPKp38δ and JNK/c-Jun signaling pathways

Investor logo
Title in English c-Myb increases resistance of colon carcinoma cells to cisplatin by activation of MAPKp38? and JNK/c-Jun signaling pathways


Year of publication 2013
Type Conference abstract
MU Faculty or unit

Faculty of Science

Description c-Myb is a transcription factor playing essential role in control of proliferation, differentiation and apoptosis of epithelial cells. Its malfunction has been associated with various tumors. Patients with colorectal carcinomas (CRC) exhibiting upregulated c-Myb expression have poor prognosis. The aim of this study was to clarify the role of c-Myb in control of the cell death/survival of colorectal carcinoma cells treated with cytotoxic agents. Our results show that the c-Myb protein reduced sensitivity of colorectal carcinoma cells to cisplatin and doxorubicin. We identified the downstream effectors mediating the effects c-Myb on cell viability - MAPKp38 and c-Jun kinases. Selective inhibitors of these kinases were used to prove the potential link between c-Myb upregulation and improved survival of colorectal cells exposed to cisplatin. Using a panel of p38 inhibitors we identified MAPKp38delta isoform (MAPK13) as a key molecule in mediating this effect. In this work, we present the possibility of a novel c-Myb-p38delta/JNK signal axis mediating increased resistance of colorectal cells to cytotoxic agents.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info